Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by NewToInvesting7on Apr 08, 2024 3:30pm
150 Views
Post# 35977445

Last 2 NRs

Last 2 NRsExtremely disappointed with the last 2 NRs from StageZero.  With a $25m credit facility available to draw from, plus the options that the BOD has that can be exercised, why is there no money to pay auditors?  Something does not smell right.

If you are managing the company and get paid a hefty compensation package (~C$500k for JHT), why not exercise some of your stock options, even if the exercise price is higher than the current SP, and use the funds to pay the auditors?  Do you not believe in the product you are selling?   

I do believe that the company has a product to sell that will generate revenues, but James Howard-Tripp has failed us yet again.  After this, I would strongly suggest that the shareholders vote out the entire board, save maybe Rory who has some skin in the game.  

Cheers! 
<< Previous
Bullboard Posts
Next >>